MapLight Therapeutics, Inc.
- MPLT
- NASDAQ
- Biotechnology
- CNS Drug Development
- Clinical-Stage Biopharma
$7.94
Today +3.12%Quote Oct 19, 2026, 04:54 PM UTC
−31.98%over the last month
Max drawdown −32.0%From 1-month high −32.0%3 months −78.6%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About MapLight Therapeutics
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders. Its pipeline features several promising therapeutic candidates: ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist, is being advanced to address symptoms of schizophrenia and Alzheimer's disease psychosis.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
133
Market value
$338.4M
Quote Oct 19
Floor
$7.90
0.5% below price
Resistance
$8.36
5.3% above price
Price vs analyst targets
7 analysts
Lowest target
$13.00Highest target
$46.00
$13.00Highest target
$46.00
- Price $7.94
- Average target $29.20
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 268% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about MPLTPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free